GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Daiichi Sankyo Co Ltd (OTCPK:DSKYF) » Definitions » EV-to-FCF

DSKYF (Daiichinkyo Co) EV-to-FCF : -39.10 (As of Mar. 05, 2025)


View and export this data going back to 2005. Start your Free Trial

What is Daiichinkyo Co EV-to-FCF?

EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Daiichinkyo Co's Enterprise Value is $41,094 Mil. Daiichinkyo Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 was $-1,051 Mil. Therefore, Daiichinkyo Co's EV-to-FCF for today is -39.10.

The historical rank and industry rank for Daiichinkyo Co's EV-to-FCF or its related term are showing as below:

DSKYF' s EV-to-FCF Range Over the Past 10 Years
Min: -92.16   Med: 33.06   Max: 537.72
Current: -35.62

During the past 13 years, the highest EV-to-FCF of Daiichinkyo Co was 537.72. The lowest was -92.16. And the median was 33.06.

DSKYF's EV-to-FCF is ranked worse than
100% of 550 companies
in the Drug Manufacturers industry
Industry Median: 23.045 vs DSKYF: -35.62

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2025-03-05), Daiichinkyo Co's stock price is $24.00. Daiichinkyo Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 was $0.849. Therefore, Daiichinkyo Co's PE Ratio (TTM) for today is 28.27.


Daiichinkyo Co EV-to-FCF Historical Data

The historical data trend for Daiichinkyo Co's EV-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Daiichinkyo Co EV-to-FCF Chart

Daiichinkyo Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
EV-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.82 43.23 71.26 181.63 16.80

Daiichinkyo Co Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
EV-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 12.44 16.80 25.90 19.60 -46.14

Competitive Comparison of Daiichinkyo Co's EV-to-FCF

For the Drug Manufacturers - General subindustry, Daiichinkyo Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Daiichinkyo Co's EV-to-FCF Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Daiichinkyo Co's EV-to-FCF distribution charts can be found below:

* The bar in red indicates where Daiichinkyo Co's EV-to-FCF falls into.



Daiichinkyo Co EV-to-FCF Calculation

Daiichinkyo Co's EV-to-FCF for today is calculated as:

EV-to-FCF=Enterprise Value (Today)/Free Cash Flow (TTM)
=41093.879/-1050.877
=-39.10

Daiichinkyo Co's current Enterprise Value is $41,094 Mil.
Daiichinkyo Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $-1,051 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Daiichinkyo Co  (OTCPK:DSKYF) EV-to-FCF Explanation

EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

Daiichinkyo Co's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=24.00/0.849
=28.27

Daiichinkyo Co's share price for today is $24.00.
Daiichinkyo Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.849.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.


Daiichinkyo Co EV-to-FCF Related Terms

Thank you for viewing the detailed overview of Daiichinkyo Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Daiichinkyo Co Business Description

Traded in Other Exchanges
Address
3-5-1, Nihonbashi-honcho, Chuo-ku, Tokyo, JPN, 103-8426
Daiichi Sankyo was established by the merger of Daiichi Pharmaceuticals and Sankyo in 2005. As of 2023, approximately one third of revenue comes from its Japan businesses, which will shrink in the future as the company expands its global footprint. Its primary growth driver is its leading platform of antibody drug conjugates, or ADCs. Its three lead ADCs are Enhertu (HER2), Dato-DXd (TROP2), I-DXd (B7-H3), HER3-DXd (HER3), and R-DXd (CDH6). Enhertu entered the clinic in 2015 and received its first US approval in December 2019 for third-line late-stage HER2-positive breast cancer. It is also approved for HER2-positive stomach cancers and HER2 mutant non-small cell lung cancer.

Daiichinkyo Co Headlines

From GuruFocus

Daiichi Sankyo Co Ltd R&D Day Transcript

By GuruFocus Research 02-13-2024

Daiichi Sankyo Co Ltd Strategy Briefing Transcript

By GuruFocus Research 02-13-2024

Q1 2022 Daiichi Sankyo Co Ltd Earnings Call Transcript

By GuruFocus Research 02-13-2024

Daiichi Sankyo Co Ltd ASCO Transcript

By GuruFocus Research 02-13-2024

Daiichi Sankyo Co Ltd ESG Briefing Transcript

By GuruFocus Research 02-13-2024

Daiichi Sankyo Co Ltd ESG Briefing Transcript

By GuruFocus Research 02-13-2024